Table 1 Open in new tab Characteristics...

Study

AF inclusion criteria

Pre-treatment drug

Pre-treatment regimen

Maintenance therapy

Acute restoration

Long-term maintenance

Mean age (years)

Mean LA diameter (mm)

Mean duration of AF (days)

Length of follow-up (months)

Boos et al.²²

Persistent AF >1 month without a reversible cause

Amiodarone

200 mg po tid for 1 week

200 mg po tid for 1 week, 200 mg po bid for 1 week, then 200 mg po od for 1 week

17/17 (100%)

8/17 (47%)

61 ± 12

41 ± 8

216 ± 126

16 ± 4

None

17/18 (94%)

3/18 (17%)

62 ± 8

44 ± 6

306 ± 180

Channer et al.²³

161

Sustained AF >72 h without a reversible cause

Amiodarone

400 mg po bid for 2 weeks

200 mg po od for 8 weeks

48/62 (77%)

21/62 (34%)

65 ± 10

44 ± 7

180 (30–2820)

Amiodarone

400 mg po bid for 2 weeks

200 mg po od for 52 weeks

48/61 (79%)

30/61 (49%)

66 ± 10

44 ± 7

180 (30–5400)

Placebo

30/38 (79%)

2/38 (5%)

68 ± 8

44 ± 7

150 (30–2520)

Galperin et al.²⁴

Chronic AF >2 months

Amiodarone

600 mg po od for 4 weeks

200 mg po od for remainder of study

35/47 (74%)

22/47 (47%)

62 ± 8

47 ± 7

1072 ± 1523

16 ± 10

Placebo

15/48 (31%)

3/48 (6%)

65 ± 6

48 ± 7

1066 ± 992

Jong et al.³⁰

Chronic AF >6 months

Amiodarone

200 mg po tid for 4 weeks

200 mg po od for 1 month, then 200 mg po qad for 1 month

39/48 (81%)

63 ± 12

51 ± 13

540 ± 360

Placebo

25/43 (58%)

62 ± 11

50 ± 12

570 ± 300

Kanoupakis et al.²⁶

Persistent AF >7 days

Amiodarone

600 mg po for 2 weeks, then 200 mg po for 2 weeks

200 mg po od for remainder of study

44/48 (92%)

64 ± 8

45 ± 4

300 ± 360

Placebo

32/47 (68%)

61 ± 10

43 ± 4

390 ± 510

Manios et al.²⁷

Persistent AF >3 months

Amiodarone

600 mg po for 2 weeks, then 200 mg po for 4 weeks

200 mg po od for 6 weeks

31/36 (86%)

66 ± 7

44 ± 6

1050 ± 870

1.5

None

26/37 (70%)

62 ± 11

43 ± 4

960 ± 1020

Singh et al.²⁸

404

Persistent AF >72 h

Amiodarone

800 mg po for 2 weeks, then 600 mg po for 2 weeks

160 mg po od for remainder of study

206/237 (77%)

134/267 (50%)

67 ± 9

49 ± 7

Placebo

90/137 (66%)

17/137 (12%)

68 ± 10

48 ± 7

Vijayalakshmi et al.²⁹

AF <1 year

Amiodarone

600 mg po for 1 week, 400 mg po for 1 week, then 200 mg po for 4 weeks

22/27 (81%)

66 ± 11

43 ± 7

198 ± 117

None

23/31 (74%)

65 ± 9

42 ± 7

210 ± 120

Table 1

Open in new tab

Characteristics of included studies

Study	N	AF inclusion criteria	Pre-treatment drug	Pre-treatment regimen	Maintenance therapy	Acute restoration	Long-term maintenance	Mean age (years)	Mean LA diameter (mm)	Mean duration of AF (days)	Length of follow-up (months)
Boos et al.²²	35	Persistent AF >1 month without a reversible cause	Amiodarone	200 mg po tid for 1 week	200 mg po tid for 1 week, 200 mg po bid for 1 week, then 200 mg po od for 1 week	17/17 (100%)	8/17 (47%)	61 ± 12	41 ± 8	216 ± 126	16 ± 4
Boos et al.²²	35	Persistent AF >1 month without a reversible cause	None	NA	NA	17/18 (94%)	3/18 (17%)	62 ± 8	44 ± 6	306 ± 180	16 ± 4
Channer et al.²³	161	Sustained AF >72 h without a reversible cause	Amiodarone	400 mg po bid for 2 weeks	200 mg po od for 8 weeks	48/62 (77%)	21/62 (34%)	65 ± 10	44 ± 7	180 (30–2820)	12
			Amiodarone	400 mg po bid for 2 weeks	200 mg po od for 52 weeks	48/61 (79%)	30/61 (49%)	66 ± 10	44 ± 7	180 (30–5400)
			Placebo	NA	NA	30/38 (79%)	2/38 (5%)	68 ± 8	44 ± 7	150 (30–2520)
Galperin et al.²⁴	95	Chronic AF >2 months	Amiodarone	600 mg po od for 4 weeks	200 mg po od for remainder of study	35/47 (74%)	22/47 (47%)	62 ± 8	47 ± 7	1072 ± 1523	16 ± 10
Galperin et al.²⁴	95	Chronic AF >2 months	Placebo	NA	NA	15/48 (31%)	3/48 (6%)	65 ± 6	48 ± 7	1066 ± 992	16 ± 10
Jong et al.³⁰	87	Chronic AF >6 months	Amiodarone	200 mg po tid for 4 weeks	200 mg po od for 1 month, then 200 mg po qad for 1 month	39/48 (81%)	NA	63 ± 12	51 ± 13	540 ± 360	2
Jong et al.³⁰	87	Chronic AF >6 months	Placebo	NA	NA	25/43 (58%)		62 ± 11	50 ± 12	570 ± 300	2
Kanoupakis et al.²⁶	94	Persistent AF >7 days	Amiodarone	600 mg po for 2 weeks, then 200 mg po for 2 weeks	200 mg po od for remainder of study	44/48 (92%)	NA	64 ± 8	45 ± 4	300 ± 360	1
Kanoupakis et al.²⁶	94	Persistent AF >7 days	Placebo	NA	NA	32/47 (68%)		61 ± 10	43 ± 4	390 ± 510	1
Manios et al.²⁷	71	Persistent AF >3 months	Amiodarone	600 mg po for 2 weeks, then 200 mg po for 4 weeks	200 mg po od for 6 weeks	31/36 (86%)	NA	66 ± 7	44 ± 6	1050 ± 870	1.5
Manios et al.²⁷	71	Persistent AF >3 months	None	NA	NA	26/37 (70%)		62 ± 11	43 ± 4	960 ± 1020	1.5
Singh et al.²⁸	404	Persistent AF >72 h	Amiodarone	800 mg po for 2 weeks, then 600 mg po for 2 weeks	160 mg po od for remainder of study	206/237 (77%)	134/267 (50%)	67 ± 9	49 ± 7	NA	12
Singh et al.²⁸	404	Persistent AF >72 h	Placebo	NA	NA	90/137 (66%)	17/137 (12%)	68 ± 10	48 ± 7	NA	12
Vijayalakshmi et al.²⁹	58	AF <1 year	Amiodarone	600 mg po for 1 week, 400 mg po for 1 week, then 200 mg po for 4 weeks	NA	22/27 (81%)	NA	66 ± 11	43 ± 7	198 ± 117	6
Vijayalakshmi et al.²⁹	58	AF <1 year	None	NA	NA	23/31 (74%)		65 ± 9	42 ± 7	210 ± 120	6

Study	N	AF inclusion criteria	Pre-treatment drug	Pre-treatment regimen	Maintenance therapy	Acute restoration	Long-term maintenance	Mean age (years)	Mean LA diameter (mm)	Mean duration of AF (days)	Length of follow-up (months)
Boos et al.²²	35	Persistent AF >1 month without a reversible cause	Amiodarone	200 mg po tid for 1 week	200 mg po tid for 1 week, 200 mg po bid for 1 week, then 200 mg po od for 1 week	17/17 (100%)	8/17 (47%)	61 ± 12	41 ± 8	216 ± 126	16 ± 4
Boos et al.²²	35	Persistent AF >1 month without a reversible cause	None	NA	NA	17/18 (94%)	3/18 (17%)	62 ± 8	44 ± 6	306 ± 180	16 ± 4
Channer et al.²³	161	Sustained AF >72 h without a reversible cause	Amiodarone	400 mg po bid for 2 weeks	200 mg po od for 8 weeks	48/62 (77%)	21/62 (34%)	65 ± 10	44 ± 7	180 (30–2820)	12
			Amiodarone	400 mg po bid for 2 weeks	200 mg po od for 52 weeks	48/61 (79%)	30/61 (49%)	66 ± 10	44 ± 7	180 (30–5400)
			Placebo	NA	NA	30/38 (79%)	2/38 (5%)	68 ± 8	44 ± 7	150 (30–2520)
Galperin et al.²⁴	95	Chronic AF >2 months	Amiodarone	600 mg po od for 4 weeks	200 mg po od for remainder of study	35/47 (74%)	22/47 (47%)	62 ± 8	47 ± 7	1072 ± 1523	16 ± 10
Galperin et al.²⁴	95	Chronic AF >2 months	Placebo	NA	NA	15/48 (31%)	3/48 (6%)	65 ± 6	48 ± 7	1066 ± 992	16 ± 10
Jong et al.³⁰	87	Chronic AF >6 months	Amiodarone	200 mg po tid for 4 weeks	200 mg po od for 1 month, then 200 mg po qad for 1 month	39/48 (81%)	NA	63 ± 12	51 ± 13	540 ± 360	2
Jong et al.³⁰	87	Chronic AF >6 months	Placebo	NA	NA	25/43 (58%)		62 ± 11	50 ± 12	570 ± 300	2
Kanoupakis et al.²⁶	94	Persistent AF >7 days	Amiodarone	600 mg po for 2 weeks, then 200 mg po for 2 weeks	200 mg po od for remainder of study	44/48 (92%)	NA	64 ± 8	45 ± 4	300 ± 360	1
Kanoupakis et al.²⁶	94	Persistent AF >7 days	Placebo	NA	NA	32/47 (68%)		61 ± 10	43 ± 4	390 ± 510	1
Manios et al.²⁷	71	Persistent AF >3 months	Amiodarone	600 mg po for 2 weeks, then 200 mg po for 4 weeks	200 mg po od for 6 weeks	31/36 (86%)	NA	66 ± 7	44 ± 6	1050 ± 870	1.5
Manios et al.²⁷	71	Persistent AF >3 months	None	NA	NA	26/37 (70%)		62 ± 11	43 ± 4	960 ± 1020	1.5
Singh et al.²⁸	404	Persistent AF >72 h	Amiodarone	800 mg po for 2 weeks, then 600 mg po for 2 weeks	160 mg po od for remainder of study	206/237 (77%)	134/267 (50%)	67 ± 9	49 ± 7	NA	12
Singh et al.²⁸	404	Persistent AF >72 h	Placebo	NA	NA	90/137 (66%)	17/137 (12%)	68 ± 10	48 ± 7	NA	12
Vijayalakshmi et al.²⁹	58	AF <1 year	Amiodarone	600 mg po for 1 week, 400 mg po for 1 week, then 200 mg po for 4 weeks	NA	22/27 (81%)	NA	66 ± 11	43 ± 7	198 ± 117	6
Vijayalakshmi et al.²⁹	58	AF <1 year	None	NA	NA	23/31 (74%)		65 ± 9	42 ± 7	210 ± 120	6

AF, atrial fibrillation; LA, left atrium; NA, not applicable.

This Feature Is Available To Subscribers Only